MX2023014547A - Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). - Google Patents
Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3).Info
- Publication number
- MX2023014547A MX2023014547A MX2023014547A MX2023014547A MX2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- indacen
- hexahydro
- sulfonamide
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141028180 | 2021-06-23 | ||
| PCT/EP2022/067126 WO2022268935A2 (en) | 2021-06-23 | 2022-06-23 | Novel process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014547A true MX2023014547A (es) | 2024-04-29 |
Family
ID=82458485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014547A MX2023014547A (es) | 2021-06-23 | 2022-06-23 | Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240150291A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4359385A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024524215A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240024842A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118019727A (cg-RX-API-DMAC7.html) |
| AR (1) | AR126215A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022300325A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219597A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308071A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014547A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202317514A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022268935A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240148839A (ko) * | 2022-02-15 | 2024-10-11 | 에프. 호프만-라 로슈 아게 | 1,2,3,5,6,7-헥사히드로-s-인다센 유도체 제조를 위한 공정 |
| EP4638422A1 (en) * | 2022-12-23 | 2025-10-29 | F. Hoffmann-La Roche AG | Proccesses for the preparation of an nlrp3 inhibitor |
| WO2025036914A1 (en) | 2023-08-16 | 2025-02-20 | F. Hoffmann-La Roche Ag | Process for the preparation of preparing 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA917435B (en) * | 1990-09-26 | 1992-05-27 | Takeda Chemical Industries Ltd | Herbicides |
| CA2059450A1 (en) * | 1991-01-24 | 1992-07-25 | Nobuyuki Sakashita | Subsituted pyridinesulfonamide compound or its salt, process for preparing the same, and herbicide containing the same |
| EP0981526B1 (en) * | 1997-05-02 | 2004-02-25 | Dr. Reddy's Laboratories Ltd. | Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| DK1340757T3 (da) * | 2000-11-16 | 2007-02-12 | Sankyo Co | 1-methylcarbapenemderivater |
| EP1403255A4 (en) * | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | RHO KINASE INHIBITORS |
| CN100360130C (zh) * | 2002-04-18 | 2008-01-09 | 先灵公司 | 用作组胺h3拮抗剂的1-(4-哌啶基)苯并咪唑酮 |
| EP1677783A2 (en) * | 2003-10-08 | 2006-07-12 | Nicholas Piramal India Limited | Fibrinogen receptor antagonists and their use |
| DOP2006000009A (es) * | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
| ZA200904857B (en) * | 2007-02-22 | 2010-09-29 | Merck Serono Sa | Quinoxaline compounds and use thereof |
| US20120196889A1 (en) * | 2009-02-25 | 2012-08-02 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
| JP5898962B2 (ja) * | 2012-01-11 | 2016-04-06 | 東京応化工業株式会社 | レジスト組成物及びレジストパターン形成方法 |
| WO2017095758A1 (en) * | 2015-12-01 | 2017-06-08 | Merck Sharp & Dohme Corp. | Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use |
| CN110914256A (zh) * | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| TW201910314A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| CN111902141A (zh) * | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| CR20200588A (es) * | 2018-05-04 | 2021-06-24 | Inflazome Ltd | Compuestos novedosos |
| CR20210148A (es) * | 2018-09-21 | 2021-05-18 | Novartis Ag | Compuestos de isoxazol carboxamida y usos de los mismos |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020157069A1 (en) * | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
| CN111393415B (zh) * | 2020-04-30 | 2020-11-20 | 苏州信诺维医药科技有限公司 | 一种杂芳腈类化合物及其应用 |
-
2022
- 2022-06-23 KR KR1020237044161A patent/KR20240024842A/ko active Pending
- 2022-06-23 CA CA3219597A patent/CA3219597A1/en active Pending
- 2022-06-23 IL IL308071A patent/IL308071A/en unknown
- 2022-06-23 TW TW111123528A patent/TW202317514A/zh unknown
- 2022-06-23 CN CN202280045202.0A patent/CN118019727A/zh active Pending
- 2022-06-23 EP EP22738569.7A patent/EP4359385A2/en active Pending
- 2022-06-23 MX MX2023014547A patent/MX2023014547A/es unknown
- 2022-06-23 WO PCT/EP2022/067126 patent/WO2022268935A2/en not_active Ceased
- 2022-06-23 JP JP2023578919A patent/JP2024524215A/ja active Pending
- 2022-06-23 AR ARP220101651A patent/AR126215A1/es unknown
- 2022-06-23 AU AU2022300325A patent/AU2022300325A1/en active Pending
-
2023
- 2023-12-19 US US18/545,711 patent/US20240150291A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4359385A2 (en) | 2024-05-01 |
| US20240150291A1 (en) | 2024-05-09 |
| IL308071A (en) | 2023-12-01 |
| WO2022268935A2 (en) | 2022-12-29 |
| CN118019727A (zh) | 2024-05-10 |
| KR20240024842A (ko) | 2024-02-26 |
| AU2022300325A8 (en) | 2023-11-16 |
| JP2024524215A (ja) | 2024-07-05 |
| AU2022300325A1 (en) | 2023-11-02 |
| CA3219597A1 (en) | 2022-12-29 |
| TW202317514A (zh) | 2023-05-01 |
| WO2022268935A3 (en) | 2023-02-02 |
| AR126215A1 (es) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004431A (es) | Procesos novedosos. | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| WO2024120378A3 (en) | Triazole compounds, preparation methods and medicinal uses thereof | |
| JOP20210307A1 (ar) | مثبطات جسيم التهابي nlrp3 | |
| MX2023007218A (es) | Cocristal de un inhibidor de cinasa dependiente de ciclina (cdk). | |
| GEAP202315746A (en) | Protein tyrosine phosphatase inhibitors | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| WO2022268935A3 (en) | Process for the preparation of nlrp3 inhibitors | |
| MX2020011196A (es) | Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. | |
| MX2023003627A (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer. | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| CA3200722A1 (en) | Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| MX2025014163A (es) | Azinas condensadas como inhibidores de tyk2 y usos de las mismas | |
| MX2025001865A (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| MX2025012370A (es) | Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta | |
| MX2023015377A (es) | Sal de potasio cristalina de 1-etil-n-((1,2,3,5,6,7-hexahidro-s-in dacen-4-il)carbamoil)piperidin-4-sulfonamida. | |
| CA3242600A1 (en) | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| MX2023014784A (es) | Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. | |
| GEAP202316371A (en) | Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide |